Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Merck’s TROP2 ADC extends survival in pivotal cancer trial
Sac-TMT improved overall survival in a phase 3 cancer trial, delivering a second pivotal global win for the TROP2-directed antibody-drug conjugate.
Nick Paul Taylor
Nov 20, 2026 11:20am
Kyntra drops mid-stage ADC, adding to years of stumbles
Nov 17, 2026 10:40am
Boehringer bags $7.4B Sino deal for 6 preclinical TCEs, ADCs
Nov 4, 2026 9:08am
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
Oct 28, 2026 9:00am
From RAS rivalry to leaked readouts, ESMO brought the data drama
Oct 27, 2026 8:00am
GSK’s B7-H3 ADC drives 67% cancer risk reduction in phase 3
Oct 27, 2026 3:28am